Особенности применения золедроновой кислоты в лечении остеопороза у пожилых пациентов
https://doi.org/10.37586/2686-8636-3-2025-343-350
Аннотация
Остеопороз представляет собой одну из наиболее значимых проблем медицины, особенно в условиях глобального старения населения. С увеличением продолжительности жизни растет число пациентов пожилого возраста с данной патологией, что обусловливает существенные медицинские и социально-экономические последствия. Остеопороз характеризуется снижением минеральной плотности костной ткани, что значительно увеличивает риск переломов, особенно у лиц старших возрастных групп. Эти патологические изменения не только ухудшают качество жизни пациентов, но и ведут к росту расходов на здравоохранение, а также увеличивают социальную нагрузку.
Об авторе
Е. Н. Дудинская
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России (Пироговский Университет), ОСП «Российский геронтологический научно-клинический центр»
Россия
Россия
Дудинская Екатерина Наильевна
Москва
Список литературы
1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 ; 94 (6) : 646–650. doi: 10.1016/0002-9343(93)90218-e.
2. Qaseem A., et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023 ; 176 (2) : 224–238. doi: 10.7326/M22-1034.
3. Belaya Zh. E., Belova K. Yu., Biryukova E. V., et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021 ; 24 (2) : 4–47. (In Russ.)]. doi: 10.14341/osteo12930.
4. Camacho P. M., et al. American Association of Clinical Endocrinologists / American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2020 update. Endocrine Practice. 2020 ; 26 (Suppl 1) : 1–46.
5. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. [Electronic resourse]. Rockville (MD): Office of the Surgeon General (US); 2004. Available from: https://www.ncbi.nlm.nih.gov/books/NBK45513/.
6. Raisz L. G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005 ; 115 (12) : 3318– 3325. doi: 10.1172/JCI27071.
7. Rosen C. J. The Epidemiology and Pathogenesis of Osteoporosis. In: Feingold KR, Ahmed SF, Anawalt B, et al., eds. Endotext. South Dartmouth (MA) : MDText.com, Inc. ; 020.
8. Rogers M. J., Mönkkönen J., Munoz M. A. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020 ; 139 : 115493. doi: 10.1016/j.bone.2020.115493.
9. Reid I. R., Horne A. M., Mihov B., et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 ; 379 (25) : 2407–2416. doi: 10.1056/NEJMoa1808082.
10. Black D. M., Delmas P. D., Eastell R., et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 ; 356 (18) : 1809–1822. doi: 10.1056/NEJMoa067312.
11. Serrano A. J., Begoña L., Anitua E., et al. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol. 2013 ; 29 (12) : 1005–1014. doi: 10.3109/09513590.2013.813468.
12. Davis S., Martyn-St. James M., Sanderson J., et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess. 2016 ; 20 (78) : 1–406. doi: 10.3310/hta20780.
13. Zhou J., Ma X., Wang T., Zhai S. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016 ; 27 (11) : 3289–3300. doi: 10.1007/s00198-016-3654-z.
14. Lyles K. W., Colón-Emeric C. S., Magaziner J. S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 ; 357 (18) : 1799–1809. doi: 10.1056/NEJMoa074941.
15. Yureneva S. V., Averkova V. G. Bisphosphonates for the prevention of osteoporotic fractures in postmenopausal women with osteopenia: a systematic review and meta-analysis. Osteoporosis and Bone Diseases. 2024 ; 27 (1) : 21–34. (In Russ.)]. doi: 10.14341/osteo13150.
16. Watts N. B., Adler R. A., Bilezikian J. P., et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 ; 97 (6) : 1802–1822. doi: 10.1210/jc.2011-3045.
17. Zhou J., Wang T., Zhao X., et al. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Rheumatol Ther. 2016 ; 3 (1) : 117–128. doi: 10.1007/s40744-016-0030-6.
18. Reid D. M., Devogelaer J. P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 ; 373 (9671) : 1253–1263. doi: 10.1016/S0140-6736(09)60250-6.
19. Black D. M., Reid I. R., Boonen S., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012 ; 27 (2) : 243–254. doi: 10.1002/jbmr.1494.
20. McClung M., Harris S. T., Miller P. D., et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013 ; 126 (1) : 13–20. doi: 10.1016/j.amjmed.2012.06.023.
21. Ganesan K., Goyal A., Roane D. Bisphosphonate. [Updated 2023 Jul 3]. StatPearls. Treasure Island (FL): StatPearls Publishing. 2020.
22. Sharma A., Einstein A. J., Vallakati A., et al. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol. 2014 ; 113 (11) : 1815–1821. doi: 10.1016/j.amjcard.2014.03.008.
23. Lesnyak O. M., Baranova I. A., Belaya Zh. E. Osteoporosis: A guide for physicians (Ed. by O. M. Lesnyak). (2nd ed., rev. and exp.). GEOTAR-Media. 2023. (In Russ.] ISBN: 978-5-9704-7145-6.
24. Greuter S., Schmid F., Ruhstaller T., Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008 ; 19 (12) : 2091–2092. doi: 10.1093/annonc/mdn653.
25. Anastasilakis A. D., Pepe J., Napoli N., et al. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. J Clin Endocrinol Metab. 2022 ; 107 (5) : 1441–1460. doi: 10.1210/clinem/dgab888.
26. Nicolatou-Galitis O., Kouri M., Papadopoulou E., et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019 ; 27 (2) : 383–394. doi: 10.1007/s00520-018-4501-x.
27. Ruggiero S. L., Dodson T. B., Aghaloo T., et al. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws2022 Update. J Oral Maxillofac Surg. 2022 ; 80 (5) : 920–943. doi: 10.1016/j.joms.2022.02.008.
28. Campisi G., Mauceri R., Bedogni A., Fusco V. Re: AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update. J Oral Maxillofac Surg. 2022 ; 80 (11) : 1723–1724. doi: 10.1016/j.joms.2022.07.149.
29. Khan A. A., Morrison A., Kendler D. L., et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2017 ; 20 (1) : 8–24. doi: 10.1016/j.jocd.2016.09.005.
30. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007 ; 22 (10) : 1479–1491. doi: 10.1359/jbmr.0707onj.
31. Shane E., Burr D., Abrahamsen B., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014 ; 29 (1) : 1–23. doi: 10.1002/jbmr.1998.
32. Black D. M., Geiger E. J., Eastell R., et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020 ; 383 (8) : 743–753. doi: 10.1056/NEJMoa1916525.
33. Schilcher J,. Koeppen V., Aspenberg P., Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med. 2014 ; 371 (10) : 974–976. doi: 10.1056/NEJMc1403799.
34. Roca-Ayats N., Balcells S., Garcia-Giralt N., et al. GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates. N Engl J Med. 2017 ; 376 (18) : 1794–1795. doi: 10.1056/NEJMc1612804.
35. Pérez-Núñez I., Pérez-Castrillón J. L., Zarrabeitia M. T., et al. Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. Mol Cell Biochem. 2015 ; 409 (1–2) : 45–50. doi: 10.1007/s11010-015-2510-3.
Рецензия
Для цитирования:
Дудинская Е.Н. Особенности применения золедроновой кислоты в лечении остеопороза у пожилых пациентов. Российский журнал гериатрической медицины. 2025;(3):343-350. https://doi.org/10.37586/2686-8636-3-2025-343-350
For citation:
Dudinskaya E.N. Features of zoledronic acid use in the treatment of osteoporosis in elderly patients. Russian Journal of Geriatric Medicine. 2025;(3):343-350. (In Russ.) https://doi.org/10.37586/2686-8636-3-2025-343-350
Просмотров:
21
Послать статью по эл. почте 